# US 2024/0002902 A1 · Analysis of antigen and antigen receptor interactions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002902 A1
- Document ID: US20240002902A1
- Status: Published application
- Kind: A1
- Application number: 18/313,251
- Filed: 2023-05-05
- Published: 2024-01-04
- Earliest claimed: 2022-05-06
- Assignees: 10x Genomics, Inc.
- Applicants: 10x Genomics, Inc.
- Inventors: Søren Nyboe JAKOBSEN; Malte KÜHNEMUND
- Web page: https://patentgrep.com/patent/US20240002902A1

## CPC

- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- G01N 33/505: {involving T-cells}
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates in some aspects to methods of contacting a biological sample (e.g., fresh or frozen tissue sample) with peptide-loaded detection complexes. In some aspects, the peptide-loaded detection complexes comprise antigen presenting molecule monomers or multimers that bind to antigens, reporter oligonucleotides that correspond to the antigen/antigen presenting molecule combination. In some aspects, the peptide-loaded detection complexes are tetramers. In some aspects, the tetramers bound to T cell receptors of T cells may be detected in situ. In some aspects, the tetramers bound to TCRs may be detected on an in situ platform and/or using an array comprising spatially barcoded capture agents. In some embodiments, the method comprises contacting a plurality of peptide-loaded detection complexes to clonal populations of T cells comprising TCRs of different antigen specificities.

## Claims

### Claim 1

A method for analyzing a biological sample, comprising:
a) contacting the biological sample with an antigen and a detection complex simultaneously or in any order, wherein:
the detection complex comprises an antigen-presenting molecule (APM) monomer or multimer that binds to the antigen to form an antigen-loaded detection complex, wherein the antigen-loaded detection complex is conjugated to a reporter oligonucleotide,
the reporter oligonucleotide corresponds to the antigen or a portion thereof or the antigen/APM combination in the antigen-loaded detection complex, and
the antigen-loaded detection complex binds to a receptor on and/or in a cell at a location in the biological sample;
b) contacting the biological sample with a probe or probe set that hybridizes to the reporter oligonucleotide; and
c) detecting a signal associated with the probe or probe set or a product thereof at the location in the biological sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detection complex is bound to the antigen to form the antigen-loaded detection complex prior to the contacting in a).

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the antigen and the APM form an antigen-APM monomer, and the antigen-loaded detection complex comprises one or more dimers, tetramers, pentamers, octamers, streptamers, or dodecamers of the antigen-APM monomer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the antigen comprises a peptide or a protein.

### Claim at position 6

7-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the APM is:
a Class I MHC molecule comprising an α subunit and a β2 microglobulin subunit, or
is a Class II MHC molecule comprising an α subunit and a β subunit.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the antigen-loaded detection complex comprises a scaffold covalently or non-covalently conjugated to the APM monomer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the scaffold comprises a fluorochrome, a streptavidin, or an avidin.

### Claim at position 11

13-14. (canceled)

### Claim 15 (depends on 12)

The method of claim 12, wherein the antigen-loaded detection complex comprises four MHC molecules each linked to an affinity tag that binds to the scaffold.

### Claim 16 (depends on 15)

The method of claim 15, wherein each of the four MHC molecules is bound to one molecule of an antigen peptide.

### Claim 17 (depends on 16)

The method of claim 16, wherein the antigen peptide is between 5 and 40 amino acid residues in length, inclusive.

### Claim at position 15

18-20. (canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the cell is a T cell, a B cell, or an NKT cell.

### Claim 22 (depends on 1)

The method of claim 1, wherein the receptor is a T cell receptor (TCR).

### Claim 23 (depends on 1)

The method of claim 1, wherein the reporter oligonucleotide is covalently or non-covalently conjugated to the antigen.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the reporter oligonucleotide is covalently or non-covalently conjugated to a scaffold of the antigen-loaded detection complex.

### Claim at position 21

26-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the reporter oligonucleotide comprises a barcode region for identifying the antigen or portion thereof, and wherein the barcode region comprises one or more barcode sequences.

### Claim 29 (depends on 1)

The method of claim 1, wherein the biological sample is not fixed and/or crosslinked prior to the contacting in a).

### Claim at position 24

30-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, further comprising fixing and/or crosslinking the biological sample after the contacting in a) and prior to the contacting in b).

### Claim at position 26

39-43. (canceled)

### Claim 44 (depends on 1)

The method of claim 1, wherein the antigen-loaded detection complex is not fluorescent or is not fluorescently labeled.

### Claim at position 28

45-65. (canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein the detecting in c) comprises sequential hybridization, sequencing by hybridization, sequencing by ligation, sequencing by synthesis, sequencing by binding, or a combination thereof, and/or
wherein the detecting in c) does not comprise contacting the biological sample with an antibody that binds to the antigen-loaded detection complex.

### Claim at position 30

67-105. (canceled)

### Claim 106 (depends on 1)

The method of claim 1, wherein the scaffold comprises dextran.
